Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.73 |
| ▸ | ATIC | P31939 | 1/20 | 0.73 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.62 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 12/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539615 | 0.87 | HSD17B10 (0.88) | HSD17B10HPGDCYP2C9TSHRALOX12 | |
| SCHEMBL9618861 | 0.79 | HSD17B10 (0.74) | HSD17B10HPGDCYP2C9TSHRALOX12 | |
| SCHEMBL317180 | 0.77 | THRB (1.00) | HSD17B10HPGDCYP2C9TSHRALOX12 | |
| SCHEMBL8747580 | 0.76 | HMGB1 (1.00) | HSD17B10HPGDCYP2C9TSHRALOX12 | |
| SCHEMBL27785282 | 0.75 | HMGB1 (0.77) | HSD17B10HPGDCYP2C9TSHRALOX12 | |
| SCHEMBL10343413 | 0.74 | HSD17B10 (0.67) | HSD17B10HPGDCYP2C9TSHRALOX12 | |
| SCHEMBL485235 | 0.74 | HSD17B10 (0.67) | HSD17B10HPGDCYP2C9TSHRALOX12 | |
| SCHEMBL485003 | 0.74 | HSD17B10 (0.67) | HSD17B10HPGDCYP2C9TSHRALOX12 | |
| SCHEMBL12818517 | 0.74 | HSD17B10 (0.67) | HSD17B10HPGDCYP2C9TSHRALOX12 | |
| SCHEMBL22213017 | 0.74 | HSD17B10 (0.67) | HSD17B10HPGDCYP2C9TSHRALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-04-19 | — | — | US | claimed |
| WO-2010114919-A2 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | STC.UNM (US) | 2010-10-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093917-A1 | METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER | RNASE1, DCLRE1B, FEN1 | HSD17B10 1364/4885HPGD 3439/4885CYP2C9 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.